EP Patent

EP4452261A4 — ORAL SUSPENSION OF APREMILAST

Assigned to Amgen Inc · Expires 2025-11-05 · 1y expired

What this patent protects

Patent listed against Otezla.

Drugs covered by this patent

Otezla (APREMILAST) · Amgen

Patent Metadata

Patent number: EP4452261A4
Jurisdiction: EP
Classification: —
Expires: 2025-11-05
Drug substance claim: No
Drug product claim: No
Assignee: Amgen Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.